The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Engineered protein scaffolds as next-generation antibody therapeutics
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Engineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931
Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies
De Genst, E., Silence, K., Decanniere, K., Conrath, K., Loris, R., Kinne, J., Muyldermans, S., & Wyns, L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505379103 · Cited by 676
Engineering novel binding proteins from nonimmunoglobulin domains
Binz, H. K., Amstutz, P., & Plückthun, A. (2005) · Nature Biotechnology · doi:10.1038/nbt1127 · Cited by 676
Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule
Orlova, A., Magnusson, M., Eriksson, T. L. J., Nilsson, M., Larsson, B., Höidén-Guthenberg, I., Widström, C., Carlsson, J., Tolmachev, V., Ståhl, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3521 · Cited by 568
Immunogenicity of protein therapeutics
De Groot, A. S., & Scott, D. W. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.07.011 · Cited by 545
Antibody-Drug Conjugates for Cancer Therapy
Carter, P. J., & Senter, P. D. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318172d704 · Cited by 429
Stabilization of a β-hairpin in monomeric Alzheimer's amyloid-β peptide inhibits amyloid formation
Hoyer, W., Grönwall, C., Jonsson, A., Ståhl, S., & Härd, T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711731105 · Cited by 410
Development trends for monoclonal antibody cancer therapeutics
Reichert, J. M., & Valge-Archer, V. E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2241 · Cited by 389
Drug Export Pathway of Multidrug Exporter AcrB Revealed by DARPin Inhibitors
Sennhauser, G., Amstutz, P., Briand, C., Storchenegger, O., & Grütter, M. G. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0050007 · Cited by 334
Tijink, B. M., Laeremans, T., Budde, M., Walsum, M. S.-V., Dreier, T., de Haard, H. J., Leemans, C. R., & van Dongen, G. A. M. S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2384 · Cited by 305
Alternative non-antibody scaffolds for molecular recognition
Skerra, A. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.04.010 · Cited by 300
Self-citationBosch, F., & Rosich, L. (2008) · Pharmacology · doi:10.1159/000149583 · Cited by 292
Nygren, P. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06438.x · Cited by 282
A Designed Ankyrin Repeat Protein Evolved to Picomolar Affinity to Her2
Zahnd, C., Wyler, E., Schwenk, J. M., Steiner, D., Lawrence, M. C., McKern, N. M., Pecorari, F., Ward, C. W., Joos, T. O., & Plückthun, A. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.03.028 · Cited by 256
DARPins: A new generation of protein therapeutics
Stumpp, M. T., Binz, H. K., & Amstutz, P. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.04.013 · Cited by 254
Strategies to Extend Plasma Half-Lives of Recombinant Antibodies
Kontermann, R. E. (2009) · BioDrugs · doi:10.2165/00063030-200923020-00003 · Cited by 243
Engineering of a femtomolar affinity binding protein to human serum albumin
Jonsson, A., Dogan, J., Herne, N., Abrahmsen, L., & Nygren, P.-A. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzn028 · Cited by 242
Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains
Silverman, J., Lu, Q., Bakker, A., To, W., Duguay, A., Alba, B. M., Smith, R., Rivas, A., Li, P., Le, H., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1166 · Cited by 237
Engineered protein scaffolds for molecular recognition
Skerra, A. (2000) · Journal of Molecular Recognition · doi:10.1002/1099-1352(200007/08)13:4<167::aid-jmr502>3.0.co;2-9 · Cited by 236
Self-citationTaussig, M. J., Stoevesandt, O., Borrebaeck, C. A. K., Bradbury, A. R., Cahill, D., Cambillau, C., de Daruvar, A., Dübel, S., Eichler, J., Frank, R., et al. (2007) · Nature Methods · doi:10.1038/nmeth0107-13 · Cited by 236
Self-citationTolmachev, V., Orlova, A., Pehrson, R., Galli, J., Baastrup, B., Andersson, K., Sandström, M., Rosik, D., Carlsson, J., Lundqvist, H., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1630 · Cited by 220
Obstacles and pitfalls in the PEGylation of therapeutic proteins.
Gaberc‐Porekar, V., Zore, I., Podobnik, B., & Menart, V. (2008) · PubMed · Cited by 197
Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs
Holt, L. J., Basran, A., Jones, K., Chorlton, J., Jespers, L. S., Brewis, N. D., & Tomlinson, I. M. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzm067 · Cited by 193
Fully human antibodies from transgenic mouse and phage display platforms
Lonberg, N. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.004 · Cited by 188
High-affinity single-domain binding proteins with a binary-code interface
Koide, A., Gilbreth, R. N., Esaki, K., Tereshko, V., & Koide, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700149104 · Cited by 179
Skerra, A. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06439.x · Cited by 176
Self-citationComparative ligand-binding analysis of ten human lipocalins
Breustedt, D. A., Schönfeld, D. L., & Skerra, A. (2006) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.12.006 · Cited by 175
Self-citationFriedman, M., Orlova, A., Johansson, E., Eriksson, T. L. J., Höidén-Guthenberg, I., Tolmachev, V., Nilsson, F. Y., & Ståhl, S. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.12.060 · Cited by 173
Affibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared Imaging
Lee, S. B., Hassan, M., Fisher, R., Chertov, O., Chernomordik, V., Kramer-Marek, G., Gandjbakhche, A., & Capala, J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4076 · Cited by 171
Hackel, B. J., Kapila, A., & Dane Wittrup, K. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.06.051 · Cited by 166
Identification and validation of cell surface antigens for antibody targeting in oncology
Carter, P. M., Smith, L. M., & Ryan, M. C. (2004) · Endocrine Related Cancer · doi:10.1677/erc.1.00766 · Cited by 145
Selection and characterization of Affibody ligands binding to Alzheimer amyloid β peptides
Grönwall, C., Jonsson, A., Lindström, S., Gunneriusson, E., Ståhl, S., & Herne, N. (2006) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2006.09.013 · Cited by 138
Schweizer, A., Roschitzki‐Voser, H., Amstutz, P., Briand, C., Gulotti-Georgieva, M., Prenosil, E., Binz, H. K., Capitani, G., Baici, A., Plückthun, A., et al. (2007) · Structure · doi:10.1016/j.str.2007.03.014 · Cited by 133
Harmsen, M. M., van Solt, C. B., Bemmel, A. M. V. Z.-V., Niewold, T., & van Zijderveld, F. G. (2006) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-005-0300-7 · Cited by 125
Biesalski, H. K., Frank, J., Beck, S. C., Heinrich, F., Illek, B., Reifen, R., Gollnick, H., Seeliger, M. W., Wissinger, B., & Zrenner, E. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.5.931 · Cited by 124
Engineered Cystine-Knot Peptides that Bind αvβ3 Integrin with Antibody-Like Affinities
Silverman, A. P., Levin, A. M., Lahti, J. L., & Cochran, J. R. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.11.004 · Cited by 124
Lipovšek, D., Lippow, S. M., Hackel, B. J., Gregson, M. W., Cheng, P. P., Kapila, A., & Wittrup, K. D. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.029 · Cited by 123
Schönfeld, D. L., Matschiner, G., Chatwell, L., Trentmann, S. M., Gille, H., Hülsmeyer, M., Brown, N., Kaye, P. M., Schlehuber, S., Hohlbaum, A. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813399106 · Cited by 122
Self-citationAn affibody in complex with a target protein: Structure and coupled folding
Wahlberg, E., Lendel, C., Helgstrand, M., Allard, P., Dinçbas‐Renqvist, V., Hedqvist, A., Berglund, H., Nygren, P., & Härd, T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0436086100 · Cited by 119
Henderson, K. A., Streltsov, V. A., Coley, A. M., Dolezal, O., Hudson, P. J., Batchelor, A. H., Gupta, A., Bai, T., Murphy, V. J., Anders, R. F., et al. (2007) · Structure · doi:10.1016/j.str.2007.09.011 · Cited by 118
Максимилианович, Т. В., Friedman, M., Sandström, M., Eriksson, T. L. J., Rosik, D., Hodik, M., Ståhl, S., Frejd, F. Y., & Orlova, A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.055525 · Cited by 115
Максимилианович, Т. В., Nilsson, F. Y., Widström, C., Andersson, K., Rosik, D., Gedda, L., Wennborg, A., & Orlova, A. (2006) · PubMed · Cited by 111
Getmanova, E. V., Chen, Y., Bloom, L., Gokemeijer, J., Shamah, S. M., Warikoo, V., Wang, J., Ling, V., & Sun, L. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.12.009 · Cited by 109
Schlapschy, M., Theobald, I., Mack, H. I. D., Schottelius, M., Wester, H.-J., & Skerra, A. (2007) · Protein Engineering Design and Selection · doi:10.1093/protein/gzm020 · Cited by 107
Self-citationIn vitro display technologies reveal novel biopharmaceutics
Rothe, A., Hosse, R. J., & Power, A. B. E. (2006) · The FASEB Journal · doi:10.1096/fj.05-5650rev · Cited by 105
Scolnik, P. A. (2009) · mAbs · doi:10.4161/mabs.1.2.7736 · Cited by 102
Allosteric Inhibition of Aminoglycoside Phosphotransferase by a Designed Ankyrin Repeat Protein
Kohl, A., Amstutz, P., Parizek, P., Binz, H. K., Briand, C., Capitani, G., Forrer, P., Plückthun, A., & Grütter, M. G. (2005) · Structure · doi:10.1016/j.str.2005.04.020 · Cited by 101
Monobodies: Antibody Mimics Based on the Scaffold of the Fibronectin Type III Domain
Koide, A., & Koide, S. (2006) · Humana Press eBooks · doi:10.1385/1-59745-187-8:95 · Cited by 98
Kolmar, H. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06440.x · Cited by 97
Remodeling a DNA-binding protein as a specific in vivo inhibitor of bacterial secretin PulD
Mouratou, B., Schaeffer, F., Guilvout, I., Tello, D., Pugsley, A. P., Alzari, P. M., & Pecorari, F. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702963104 · Cited by 93
A Dominant Conformational Role for Amino Acid Diversity in Minimalist Protein–Protein Interfaces
Gilbreth, R. N., Esaki, K., Koide, A., Sidhu, S. S., & Koide, S. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.06.014 · Cited by 91
Chaperone-Assisted Crystallography with DARPins
Sennhauser, G., & Grütter, M. G. (2008) · Structure · doi:10.1016/j.str.2008.08.010 · Cited by 88
Immunogenicity screening in protein drug development
Walle, I. V., Gansemans, Y., Parren, P. W. H. I., Stas, P., & Lasters, I. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.3.405 · Cited by 87
Schweizer, A., Rusert, P., Berlinger, L., Ruprecht, C. R., Mann, A. M., Corthésy, S., Turville, S. G., Aravantinou, M., Fischer, M., Robbiani, M., et al. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000109 · Cited by 77
A Novel, Non-immunogenic Fyn SH3-derived Binding Protein with Tumor Vascular Targeting Properties
Grabulovski, D., Kaspar, M., & Neri, D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m609211200 · Cited by 75
Imitating the humoral immune response
Skerra, A. (2003) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2003.10.012 · Cited by 72
Self-citationHuber, T., Steiner, D., Röthlisberger, D., & Plückthun, A. (2007) · Journal of Structural Biology · doi:10.1016/j.jsb.2007.01.013 · Cited by 70
Dineen, S. P., Sullivan, L. A., Beck, A. W., Miller, A. F., Carbon, J. G., Mamluk, R., Wong, H., & Brekken, R. A. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-352 · Cited by 68
Biopharmaceutical drug discovery using novel protein scaffolds
Gill, D. S., & Damle, N. K. (2006) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2006.10.003 · Cited by 67
Lehmann, A. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.8.1187 · Cited by 66
High-Affinity Recognition of Lanthanide(III) Chelate Complexes by a Reprogrammed Human Lipocalin 2
Kim, H., Eichinger, A., & Skerra, A. (2009) · Journal of the American Chemical Society · doi:10.1021/ja806857r · Cited by 60
Self-citationStructural Basis for Molecular Recognition in an Affibody:Affibody Complex
Lendel, C., Dogan, J., & Härd, T. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.04.043 · Cited by 60
Affilin–Novel Binding Molecules Based on Human γ-B-Crystallin, an All β-Sheet Protein
Ebersbach, H., Fiedler, E., Scheuermann, T., Fiedler, M. R. M., Stubbs, M. T., Reimann, C., Proetzel, G., Rudolph, R., & Fiedler, U. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.06.045 · Cited by 59
Attucci, S., Gauthier, A., Korkmaz, B., Delépine, P., Martino, M., Saudubray, F., Diot, P., & Gauthier, F. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.103440 · Cited by 57
The art of antibody process development
Steinmeyer, D. E., & McCormick, E. L. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.04.005 · Cited by 56
Hoyer, W., & Härd, T. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.02.040 · Cited by 43
Structure of wild-type Plk-1 kinase domain in complex with a selective DARPin
Bandeiras, T. M., Hillig, R. C., Matias, P. M., Eberspaecher, U., Fanghänel, J., Thomaz, M., Miranda, S., Crusius, K., Pütter, V., Amstutz, P., et al. (2008) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444907068217 · Cited by 38
Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins
Mukovozov, I., Sabljic, T. F., Hortelano, G., & Ofosu, F. A. (2008) · Thrombosis and Haemostasis · doi:10.1160/th07-11-0654 · Cited by 36
PEGylated DX-1000: Pharmacokinetics and Antineoplastic Activity of a Specific Plasmin Inhibitor
Devy, L., Rabbani, S. A., Stochl, M., Ruskowski, M., Mackie, I. J., Naa, L., Toews, M., van Gool, R., Chen, J., Ley, A., et al. (2007) · Neoplasia · doi:10.1593/neo.07544 · Cited by 36
Selection and characterization of an HIV‐1 gp120‐binding affibody ligand
Wikman, M., Rowcliffe, E., Friedman, M., Henning, P., Lindholm, L., Olofsson, S., & Ståhl, S. (2006) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20060016 · Cited by 34
Wurch, T., Lowe, P. R., Caussanel, V., et al. (2008) · Current Pharmaceutical Biotechnology · doi:10.2174/138920108786786385 · Cited by 31
Understanding mechanisms governing protein–protein interactions from synthetic binding interfaces
Kossiakoff, A. A., & Koide, S. (2008) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2008.06.004 · Cited by 30
Huang, J. Y., Koide, A., Nettle, K. W., Greene, G. L., & Koide, S. (2005) · Protein Expression and Purification · doi:10.1016/j.pep.2005.10.021 · Cited by 26
Fibronectin Type III Domain Based Monobody with High Avidity
Duan, J., Wu, J., Valencia, C. A., & Liu, R. (2007) · Biochemistry · doi:10.1021/bi701215e · Cited by 26
Munoz, E., & Deem, M. W. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzn007 · Cited by 26
Generation of Affibody® ligands binding interleukin‐2 receptor α/CD25
Grönwall, C., Snelders, E., Palm, A. J., Eriksson, F., Herne, N., & Ståhl, S. (2008) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20070261 · Cited by 23
Engineered protein inhibitors of proteases.
Nixon, A. E., & Wood, C. R. (2006) · PubMed · Cited by 16
Mills, J., Liu, G., Skerra, A., & Szyperski, T. (2009) · Biochemistry · doi:10.1021/bi900535j · Cited by 15
Self-citationNovel Alternative Scaffolds and Their Potential Use for Tumor Targeted Radionuclide Therapy
Frejd, F. Y. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8696-0_6 · Cited by 8
Cited by
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Strategies and challenges for the next generation of therapeutic antibodies
Beck, A., Wurch, T., Bailly, C., & Corvaia, N. (2010) · Nature Reviews Immunology · doi:10.1038/nri2747 · Cited by 847
PEGylation of therapeutic proteins
Jevševar, S., Kunstelj, M., & Porekar, V. G. (2010) · Biotechnology Journal · doi:10.1002/biot.200900218 · Cited by 681
Massively parallel de novo protein design for targeted therapeutics
Chevalier, A., Silva, D.-A., Rocklin, G. J., Hicks, D. R., Vergara, R., Murapa, P., Bernard, S. M., Zhang, L., Lam, K.-H., Yao, G., et al. (2017) · Nature · doi:10.1038/nature23912 · Cited by 453
“The inputs were composed of: (1) HB36, HB80 or Syt-II helical binding motifs (Protein Databank (PDB) IDs: 3R2X, 4EEF and 2NM1, respectively); (2) the context target protein (influenza HA or BoNT HCB); and (3) the above described library of de novo mini-protein scaffolds.”
MethodIntroduction to current and future protein therapeutics: A protein engineering perspective
Carter, P. J. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.02.013 · Cited by 467
Metadata
- Authors
- Gebauer, M., & Skerra, A.
- Venue
- Current Opinion in Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 13
- Issue
- 3
- Pages
- 245-255
- ISSN
- 1367-5931 (ISSN-L)
- OpenAlex
- W2047199560
- Cited by
- 341
- References
- 80
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.